FDA
-
-
-
-
-
-
-
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
-
-
-
-
-
-
-
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
-
-
-
-
-
-
-
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
-
-
-
-
-
-
-
Orchestra BioMed publishes clinical data on blood pressure therapy
-
-
-
-
-
-
-
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
-
-
-
-
-
-
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
-
-
-
-
-
-
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloo
-
325,892 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

